Key points are not available for this paper at this time.
To investigate management of patients who develop ipilimumab-mediated enterocolitis, including association of endoscopic findings with steroid-refractory symptoms and utility of infliximab as second-line therapy.
Jain et al. (Sun,) studied this question.